TELA - TELA Bio GAAP EPS of -$0.52 beats by $0.03 revenue of $11.6M misses by $1.59M

2023-03-21 16:07:40 ET

• TELA Bio press release ( NASDAQ: TELA ): Q4 GAAP EPS of -$0.52 beats by $0.03 .
• Revenue of $11.6M (+38.6% Y/Y) misses by $1.59M .
• Gross profit was $8.2 million in the fourth quarter of 2022, or 70% of revenue, compared to $5.7 million, or 68% of revenue, in the same period in 2021.

• Loss from operations was $9.4 million in the fourth quarter of 2022, compared to a loss from operations of $7.7 million in the same period in 2021.

• Net loss was $10.0 million in the fourth quarter of 2022, compared to a net loss of $8.6 million in the same period in 2021.

• Cash and cash equivalents on December 31, 2022 totaled $42.0 million.

  2023 Financial Guidance

  Full year 2023 revenue is projected to range from $60 million to $65 million, vs $59.59M Consensus reflecting growth of 45% to 57% over full year 2022.

For further details see: